X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with J.B.Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs J.B.CHEMICALS - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA J.B.CHEMICALS ASTRAZENECA PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 105.3 15.1 697.6% View Chart
P/BV x 15.0 2.4 628.4% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ASTRAZENECA PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
J.B.CHEMICALS
Mar-16
ASTRAZENECA PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,285318 404.0%   
Low Rs634200 317.8%   
Sales per share (Unadj.) Rs189.6148.0 128.1%  
Earnings per share (Unadj.) Rs-0.219.1 -1.1%  
Cash flow per share (Unadj.) Rs3.823.9 16.1%  
Dividends per share (Unadj.) Rs00.50 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs68.6128.9 53.2%  
Shares outstanding (eoy) m25.0084.82 29.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.7 289.4%   
Avg P/E ratio x-4,712.713.6 -34,751.5%  
P/CF ratio (eoy) x249.610.8 2,309.3%  
Price / Book Value ratio x14.02.0 696.5%  
Dividend payout %02.6 0.0%   
Avg Mkt Cap Rs m23,98821,951 109.3%   
No. of employees `0001.62.7 57.0%   
Total wages/salary Rs m1,6051,841 87.1%   
Avg. sales/employee Rs Th3,040.24,590.9 66.2%   
Avg. wages/employee Rs Th1,029.2673.4 152.8%   
Avg. net profit/employee Rs Th-3.3592.1 -0.6%   
INCOME DATA
Net Sales Rs m4,74012,551 37.8%  
Other income Rs m92542 17.0%   
Total revenues Rs m4,83213,093 36.9%   
Gross profit Rs m-1302,055 -6.3%  
Depreciation Rs m101412 24.5%   
Interest Rs m096 0.0%   
Profit before tax Rs m-1392,088 -6.7%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5469 1.1%   
Profit after tax Rs m-51,619 -0.3%  
Gross profit margin %-2.716.4 -16.7%  
Effective tax rate %-3.722.5 -16.3%   
Net profit margin %-0.112.9 -0.8%  
BALANCE SHEET DATA
Current assets Rs m2,7267,778 35.1%   
Current liabilities Rs m2,4354,358 55.9%   
Net working cap to sales %6.127.2 22.6%  
Current ratio x1.11.8 62.7%  
Inventory Days Days7455 134.9%  
Debtors Days Days4180 50.9%  
Net fixed assets Rs m1,0355,713 18.1%   
Share capital Rs m50170 29.5%   
"Free" reserves Rs m94210,547 8.9%   
Net worth Rs m1,71610,937 15.7%   
Long term debt Rs m00-   
Total assets Rs m4,15615,574 26.7%  
Interest coverage xNM22.8-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.8 141.5%   
Return on assets %-0.111.0 -1.1%  
Return on equity %-0.314.8 -2.0%  
Return on capital %020.0 0.0%  
Exports to sales %5.748.7 11.7%   
Imports to sales %6.57.1 91.3%   
Exports (fob) Rs m2706,115 4.4%   
Imports (cif) Rs m306889 34.5%   
Fx inflow Rs m3756,169 6.1%   
Fx outflow Rs m4701,285 36.6%   
Net fx Rs m-964,884 -2.0%   
CASH FLOW
From Operations Rs m-81,397 -0.6%  
From Investments Rs m-146-320 45.5%  
From Financial Activity Rs m862-1,196 -72.1%  
Net Cashflow Rs m709-102 -692.6%  

Share Holding

Indian Promoters % 0.0 55.4 -  
Foreign collaborators % 75.0 0.3 25,000.0%  
Indian inst/Mut Fund % 0.3 3.4 8.8%  
FIIs % 15.7 3.9 402.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 37.0 24.6%  
Shareholders   12,856 30,437 42.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS